elegslab Inc. is a biotech startup developing an AI-based drug screening platform utilizing Caenorhabditis elegans (C. elegans). This platform provides a solution that can simultaneously evaluate both the efficacy and toxicity of drug candidates through a microfluidic chip?based automated experimental system and high-resolution image analysis algorithms.

Its core technologies include a multidimensional analysis chip capable of extracting both behavioral data and molecular/cellular responses within the same organism, as well as an AI-powered system that automatically predicts drug activity based on the collected data.

With the rapid global shift toward strengthening animal welfare and alternative-to-animal testing regulations, ElexLab’s solution meets both technological and societal demands.

The AI-C. elegans-based drug discovery platform is a nonclinical CRO technology that utilizes AI to analyze the responses of C. elegans to drug candidates, thereby assessing their toxicity and efficacy. The C. elegans model occupies a unique position in areas such as reproductive toxicity, metabolic disorders, neurodegenerative diseases, and age-related conditions, where cell-based assays and organoid analyses are not feasible. As such, it offers a distinct competitive advantage as a nonclinical CRO in these specialized fields. C. elegans enables the collection of large-scale data from numerous individuals, and its short life cycle facilitates rapid data acquisition. It is possible to reduce both the time and cost of drug development by leveraging big data-driven predictive models.